(Q38069896)

28 August 2017

1 reference

title

Ticagrelor: the first novel reversible P2Y(12) inhibitor (English)

1 reference

28 August 2017

2

Steven R Steinhubl

1 reference

28 August 2017

Wah Wah Htun

1

1 reference

28 August 2017

language of work or name

English

0 references

publication date

27 December 2012

1 reference

Expert Opinion on Pharmacotherapy

28 August 2017

published in

1 reference

28 August 2017

volume

14

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

237-245

1 reference

A new era for antiplatelet therapy in patients with acute coronary syndrome

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Current concepts of the pathogenesis of the acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Adenosine release: a potential explanation for the benefits of ticagrelor in the PLATelet inhibition and clinical outcomes trial?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

The reversible oral P2Y12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Ticagrelor: a review of its use in the management of acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Intravenous adenosine and dyspnea in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.757303

10.1517/14656566.2013.757303

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference